Starting with our financial results for this second quarter, we have posted sales and profits from Optos Plc, a U.K.-based retina diagnostic imaging equipment company whose acquisition we completed at the end of May 2015. During the year ending March 2016, we will be posting about three quarters' worth of sales from Optos Plc. It should be noted that those sales will account for almost all of the approximately 15.0 billion yen in full-year net sales for our Medical Business as a whole. While we anticipate that the full-year operating income margin at Optos Plc will be more than 10%, which is in line with our initial target for the year, our Medical Business has incurred considerable segment expenses due to advance investment aimed at medium-term business growth. Consequently, we predict that for this segment as a whole, a full-year operating loss will be approximately 6.0 billion yen, which is also in line with our initial target for the year.